Actively Recruiting

Age: 18Years - 85Years
All Genders
NCT07491016

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

Led by Zhejiang Provincial People's Hospital · Updated on 2026-03-30

30

Participants Needed

1

Research Sites

108 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients

CONDITIONS

Official Title

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-85 years
  • Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR diagnostic criteria
  • Traditional disease-modifying rheumatic drug treatments have been ineffective
  • Use of two or more biological or targeted disease-modifying anti-rheumatic drugs has been ineffective
  • Patients require treatment with telitacicept combined with tofacitinib
  • Voluntary written informed consent provided
Not Eligible

You will not qualify if you...

  • Severe diseases of major organs such as heart, liver, or lungs
  • Malignancies, blood disorders, or other autoimmune diseases besides rheumatoid arthritis
  • History of allergy or hypersensitivity to telitacicept or tofacitinib
  • Active tuberculosis or infectious diseases needing systemic treatment
  • Pregnancy, breastfeeding, or refusal to use contraception during the study
  • Failure to complete the telitacicept and tofacitinib treatment due to non-adherence or severe side effects
  • Other conditions that the investigator judges as reasons for exclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

Z

Zhenhua Ying

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis | DecenTrialz